FDA Approved: UROXATRAL — Supplemental Application (Advanz Pharma (US) Corp.)

View source ↗

Summary

FDA approved a supplemental application for UROXATRAL (alfuzosin hydrochloride) submitted by Advanz Pharma (US) Corp., through a supplemental NDA.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Benign Prostatic Hyperplasia

Drugs mentioned

• Uroxatral (Alfuzosin)

Snippet

SUPPL AP for UROXATRAL (ALFUZOSIN HCL)